Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.71 |
| ▸ | MAOB | P27338 | 8/20 | 0.71 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 1/20 | 0.56 |
| ▸ | CDK4 | P11802 | 1/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.56 |
| ▸ | CCND1 | P24385 | 1/20 | 0.56 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
| ▸ | TOP1 | P11387 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9265860 | 0.87 | RAB9A (0.82) | MAOAMAOBALOX5RAB9ALCK | |
| SCHEMBL13802183 | 0.86 | CCNB2 (0.76) | MAOAMAOBALOX5RAB9ALCK | |
| SCHEMBL158270 | 0.84 | RAB9A (0.68) | MAOAMAOBRAB9ALCKGSK3B | |
| SCHEMBL314161 | 0.83 | MAOB (1.00) | MAOAMAOBRAB9ALCKNPC1 | |
| SCHEMBL29454637 | 0.83 | MAOB (1.00) | MAOAMAOBRAB9ALCKNPC1 | |
| SCHEMBL449062 | 0.83 | PLA2G4A (0.53) | MAOAMAOBRAB9A | |
| SCHEMBL865349 | 0.83 | RAB9A (0.71) | MAOAMAOBRAB9ALCKGSK3B | |
| SCHEMBL1164139 | 0.83 | MAOB (0.74) | MAOAMAOBRAB9ALCKNPC1 | |
| SCHEMBL450985 | 0.82 | S1PR1 (0.52) | MAOAMAOBRAB9AMTNR1A | |
| SCHEMBL1481374 | 0.82 | KDM4E (0.77) | MAOBALOX5LCKGSK3BBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | US | disclosed |
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | US | disclosed |
| EP-1680397-A2 | NOVEL COMPOUNDS AND THEIR USE AS ANTIDIABETIC AND HYPOLIPIDEMIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dr. Reddy's Laboratories Ltd. (IN) | 2006-07-19 | — | — | EP | disclosed |
| US-20060100261-A1 | Furan or thiopene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-05-11 | — | — | US | disclosed |
| US-5594016-A | ANTIDIABETIC AGENTS | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-01-14 | — | — | US | disclosed |
| EP-0604983-B1 | Naphthalene derivatives | MITSUBISHI CHEM CORP (JP) | 1996-11-20 | — | — | EP | disclosed |
| EP-0589484-B1 | 1,2-Ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO LTD (JP) | 1996-10-16 | — | — | EP | disclosed |
| US-5472984-A | 1,2-ethanediol derivative and salt thereof and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1995-12-05 | — | — | US | disclosed |
| EP-0604983-A1 | Naphthalene derivatives | Mitsubishi Chemical Corporation (JP) | 1994-07-06 | — | — | EP | disclosed |
| EP-0589484-A1 | 1,2-Ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-03-30 | — | — | EP | disclosed |
| EP-0587194-A1 | 2-(Heterocycloalkoxy)-1-(subst.-phenyl)-ethanol derivatives as cerebral function improving agents | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-03-16 | — | — | EP | disclosed |
| EP-0587193-A1 | 1,2-Ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-03-16 | — | — | EP | disclosed |
| US-5280032-A | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-01-18 | — | — | US | disclosed |
| EP-0383281-A1 | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1990-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | MAOA 1163/4885MAOB 1049/4885ALOX5 2676/4885 |
| US-20060100261-A1 | Furan or thiopene derivative and medicinal use thereof | TXN2, CYP11B2, CYP11B1 | MAOA 3320/4885MAOB 2227/4885ALOX5 246/4885 |
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | GPR119, NR1H3, NR1H2 | MAOA 3624/4885MAOB 2660/4885ALOX5 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.